The best way to prevent and minimize cardiac problems is to diagnose and treat them before they become problems. The main goal of the IQ2™ technology is to do just that. An objective and accurate assessment can provide valuable data for a clinician to work with to provide accurate treatment options that could prevent further complications and improve the quality and longevity of his patient's life.

Early IQ2™ hemodynamic evaluation allows earlier optimization of circulatory functions resulting in improved clinical and financial outcomes. Shoemaker, WC., 2003

Company | Products | Patient Monitoring | Clinical Trials | Corporate Relations | Abstract/Case Studies | News | Contact
©2008, All Rights Reserved, NMT, Inc. | ETag™, IQ2™ and NcIQ™ are not yet FDA approved for sale